GPGabor C. Petzold

Gabor C. Petzold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gabor C. Petzold has a total of 900 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional outcomes and quality of life after endovascular thrombectomy in large and extensive infarcts (ASPECTS 0–5): a multicentre registry study

    by Hannah Asperger, Felix J Bode, Taraneh Ebrahimi, Lara Klehr, Julia Layer, Julius Meißner, Louisa Nitsch, Omid Shirvani, Christian S Thielscher, Niklas M von Danwitz, et al.

    Introduction: Endovascular thrombectomy (EVT) is established for large infarcts, but remains cautiously applied in extensive infarcts with an Alberta Stroke Program Early CT Score (ASPECTS) of 0–2. Real-life outcome data remain limited. Patients and methods: Retrospective analysis of the German Stroke Registry-Endovascular Treatment comparing extensive (ASPECTS 0–2) and large infarcts (ASPECTS 3–5) in patients with anterior-circulation occlusion and EVT. The primary outcome was the ordinal 90-day mRS distribution; secondary outcomes were mRS 0–3, survival, quality of life (3-level European Quality of Life-5 Dimensions) and living condition. Results: Of 18,069 screened patients, 889 were analysed (ASPECTS 1–2, n = 89; ASPECTS 3–5, n = 800); none had ASPECTS 0. With ASPECTS 1–2, 20.2% achieved mRS 0–3 and 55.1% died within 90 days. In the model including successful reperfusion, no statistically significant association was detected between infarct group and the 90-day mRS distribution (common odds ratio [cOR] 0.80; 95% CI, 0.53–1.23) or mRS 0–3 (adjusted odds ratio [aOR] 0.89; 95% CI, 0.64–1.25), whereas successful reperfusion was associated with both (cOR 3.68; 95% CI, 2.31–5.85 and aOR 4.10; 95% CI, 2.45–6.86). Among survivors, median European Quality of Life-5 Dimensions utility index was 0.445 vs 0.541 (n = 27/324), and 51.5% vs 50.9% lived at home (n = 33/411). Discussion: An extensive infarct carried a challenging prognosis, yet acceptable outcome and non-institutional living remained achievable in a relevant minority. An independent association of infarct group with outcome was not detected. Conclusion: An acceptable outcome remained attainable in selected patients with extensive infarction, particularly after successful reperfusion. Lacking a medically managed comparator, these data describe prognosis rather than treatment effect.

  • Open Access

    Proximity-extension dementia-panel in 41 brain disorders: a meta-analysis

    by Elena-Raluca Blujdea, Yanaika Hok-A-Hin, Adrian-Minh Schumacher, Jodi Maple-Grødem, Amanda Cano, Muhammad Ali, Richard Price, Andreas Göteson, Ahmed Abdelhak, Aitana Sogorb-Esteve, et al.

    Fluid biomarkers detectable in cerebrospinal fluid (CSF) and blood offer critical insights into neurodegenerative disorders 1-5 , such as Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies 6-9 . Previous proximity-extension assay (PEA) studies have discovered 42 CSF biomarkers for distinguishing the aforementioned dementias 6-9 ; however, their disease- and matrix-specificity remain understudied. We developed and employed a federated meta-analysis framework to explore these biomarkers by analysing results from 65 case-control cohorts, including 20,576 samples (CSF n = 8,766, blood n = 11,810) covering 41 neurological and psychiatric conditions. Our comprehensive analysis identified both distinct and shared patterns of protein alterations across the spectrum of brain disorders, with marked differences observed between CSF and blood profiles. While several biomarkers demonstrated significant changes within their primary disease contexts, we also observed convergent dysregulation of proteins related to neuroinflammation and tau pathology across multiple conditions. These findings highlight the importance of fluid-specific biomarker assessment and provide a resource to inform the development and contextualization of novel biomarkers for brain disorders.

  • Open Access

    Large Core Stroke Thrombectomy Is Safe and Effective Regardless of Prior Antithrombotic or Thrombolytic Treatment: A Secondary Analysis of the Randomized TENSION Trial

    by Eckhard Schlemm, Märit Jensen, Maximilian Schell, Jens Fiehler, Fabien Subtil, Susanne Bonekamp, Anne Hege Aamodt, Blanca Fuentes, Elke R. Gizewski, Michael D. Hill, et al.

    Background: The relevance of prior antithrombotic and thrombolytic treatment for decision‐making regarding endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion with established large infarcts is uncertain. This study investigates associations of prior antithrombotic medication and thrombolysis with the efficacy and safety of EVT for acute ischemic stroke due to large vessel occlusion with established large infarct. Methods: TENSION (Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window) was a prospective randomized open‐label blinded–end point clinical trial. Patients with acute ischemic stroke due to large vessel occlusion and established large infarct were randomized to EVT with medical therapy or medical therapy alone. Exposures were preadmission antithrombotic treatment with antiplatelet agents or anticoagulants and intravenous thrombolysis. The primary efficacy end point was functional outcome at 90 days. Safety outcomes included death and symptomatic intracranial hemorrhage. Results: The study included 246 patients (median age, 74 years; interquartile range, 65 to 80 years; 49% women); 124 (50%) were assigned to EVT. Of 176 patients (72%) with prior antithrombotic therapy, 75 (31%) received antiplatelets, 56 (23%) anticoagulants, and 89 (36%) intravenous thrombolysis. EVT was associated with better functional outcome in patients with (common odds ratio [cOR], 2.40 [95% CI, 1.22–4.99]) and without (cOR, 2.29 [95% CI, 1.53–3.46]) antiplatelet therapy; with (cOR, 2.45 [95% CI, 1.17–5.28]) and without (cOR, 2.12 [95% CI, 1.44–3.15]) anticoagulation; as well as receiving (cOR, 1.46 [95% CI, 0.83–2.61]) and not receiving (cOR, 2.89 [95% CI, 1.87–4.51]) thrombolysis. Interaction analyses were consistent with similar treatment effects across subgroups. Mortality and rates of symptomatic intracranial hemorrhage were similar between groups. Conclusions: Benefit and safety of EVT were not modified by prior antithrombotic/thrombolytic therapy. Preadmission exposure to antiplatelets or anticoagulants or use of intravenous thrombolysis should not exclude eligible patients with stroke from EVT. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03094715.

  • Real-World Validation of the HERMES-24 Score for Outcome Prediction After Large Vessel Occlusion Treatment in Late Time Window Patients

    by Omid Shirvani, Felix J. Bode, Sebastian Stösser, Hannah Asperger, Taraneh Ebrahimi, Lara Klehr, Julia Layer, Julius Meissner, Svenja Odensass, Anna Skobel, et al.

    ObjectivesThe HERMES-24 score recently demonstrated high accuracy for outcome prediction after large vessel occlusion (LVO) treatment in late time window patients from randomized clinical trials. I...

  • Open Access

    Hierarchical composite outcomes in acute ischaemic stroke with large infarct: a win ratio analysis of the TENSION trial

    by Olga Ciobanu-Caraus, Philip Heesen, Michael D Hill, Susanne Bonekamp, Jens Fiehler, Anne Hege Aamodt, Blanca Fuentes, Elke R Gizewski, Antonin Krajina, Laurent Pierot, et al.

    Introduction: Traditional endpoints in acute ischaemic stroke trials, most commonly the mRS, incompletely capture the full spectrum of patient outcomes. The win ratio (WR) is a hierarchically structured composite outcome measure that prioritises endpoints according to clinical importance. In this study, we applied win statistics to investigate which components drive the overall treatment effect. Patients and methods: Of 253 patients in the TENSION (Efficacy and safety of ThrombEctomy iN Stroke with extended leSION and extended time window) trial, 125 were randomised to EVT + BMT and 128 to BMT alone. Endpoints were ranked hierarchically: (1) time to death, (2) mRS at 12 months, (3) occurrence of any serious adverse event and (4) EuroQOL 5-dimension scores at 12 months. Outcomes were analysed using win statistics. Results: The overall WR was 1.61 (95% CI, 1.19–2.18; P = .002), indicating a relative frequency of wins for EVT + BMT of approximately 60% among untied pairwise comparisons. The win difference was 22.8% (95% CI, 8.3%–36.3%; P = .002), of which 15.7% were attributable to survival. Win ratios were consistent across prespecified subgroups, including both sexes, age ≤ 80 years, baseline mRS 0–1, conscious patients, ASPECTS 5 and M1 occlusions. Discussion: The WR provides an informative complement to conventional mRS-based analyses in acute ischaemic stroke trials. Our hierarchical composite outcome analysis demonstrated how ordering of hierarchical components affects the resulting estimates, with the predominant treatment effect in TENSION being driven by improved survival. Conclusion: These findings support the complementary use of hierarchical composite outcomes in future neurointerventional trials.


  • Open Access

    Privacy-Preserving Mobile Face Tracking for Assessing Empathic Facial Reactivity: Cross-Sectional Study in Healthy Adults (Preprint)

    by Cem Doğdu, Leon Nissen, Luca Kleineidam, Carolin Miklitz, Johanna Knöferle, Klaus Fliessbach, Lena Marth, Johannes Levin, Elisabeth Kasper, Andreas Hermann, et al.

  • Open Access

    Alzheimer's Disease Co‐Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis

    by Elisabeth Kasper, Annaliis Lehto, Alexandra Jürs, Nina Nordmann, Oliver Peters, Julian Hellmann, Josef Priller, Eike Jakob Spruth, Gabor C. Petzold, Ina Voigt, et al.

    Objectives: Amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) share neuropathological features, including tau, amyloid, and TDP‐43 pathology. This study investigated whether AD‐related pathological changes are associated with cognitive impairment ALS. Methods: Cerebrospinal fluid (CSF total‐tau, phosphorylated‐tau, beta‐amyloid) and plasma biomarkers (TDP‐43; neurofilament light chain [NfL]) were analyzed in 192 individuals with ALS or ALS with frontotemporal dementia (ALS‐FTD) and 100 healthy controls. Cognitive performance was assessed using the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Group comparisons and regression analyses examined associations between biomarker profiles and cognitive status. Autopsy data were available for a subset of participants. Results: Compared with healthy controls, patients with ALS – particularly those with cognitive impairment (ALSci) or ALS‐FTD – showed elevated AD‐related biomarkers. Significant differences in beta‐amyloid levels were observed between healthy controls (HCs) and patients with ALSci, but not between controls and cognitively unimpaired patients. CSF p‐tau and total‐tau levels were strongly associated with domain‐specific cognitive performance. In contrast, plasma extracellular vesicle TDP‐43 and NfL showed weak or no association with cognition. In vivo biomarkers alone reliably distinguished cognitive impairment only in ALSci and ALS‐FTD. Postmortem analyses showed no strong association between ABC scores or overall TDP‐43 burden and cognitive state; however, temporal and hippocampal TDP‐43 burden was associated with cognitive dysfunction. Interpretation: Our findings suggest that tau‐related CSF biomarkers, particularly p‐tau and total‐tau, are associated with cognitive deficits in ALS, indicating that AD‐related pathology might be associated to cognitive decline in ALS. However, postmortem data showed even stronger relation of TDP43 pathology to cognitive deficits in ALS. ANN NEUROL 2026;100:123–138


  • Open Access

    Neuroinflammation and neurodegeneration trigger a specific splice form of ribosomal protein S24

    by Srivathsa S Magadi, Maria Jonson, Pablo B Lucena, Michele F Caliandro, Beatriz Almeida, Lorina Bilalli, Dimitri Budinger, Anna Tsoi, Maria Ntzouni, Joseph Agi Maqdissi, et al.

    Neuroinflammation, particularly that involving reactive microglia, the brain’s resident immune cells, is implicated in the pathogenesis of major neurodegenerative diseases (NDs). Multiple studies have reported changes in ribosomal protein (RP) expression during neurodegeneration, but the significance of these changes remains unclear. Ribosomes are evolutionarily conserved protein-synthesizing machines; although commonly viewed as invariant, accumulating evidence suggests functional ribosome specialization through variation in their protein composition. Among RPs, S24, encoded by RPS24 in humans and Rps24 in mice, is unique as its transcripts undergo alternative splicing to produce protein variants with different C-terminal sequences that are differentially expressed across tissues and cell types. Understanding heterogeneous RP expression patterns across brain regions and cell types could reveal mechanisms underlying selective vulnerability in NDs and provide new biomarkers for neuroinflammatory responses. To characterize RP expression patterns across brain regions in neurons, astrocytes and microglia, we analysed cell type-specific translating mRNAs from mice. To investigate Rps24 isoform-specific expression, we performed cell type-resolved transcript analysis and developed antibodies specific for the S24-PKE protein variant encoded by mRNA isoform Rps24c. We examined Rps24c/S24-PKE expression in brains from mouse models of ageing and neurodegeneration, as well as in human post-mortem tissue from patients with Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). This work revealed distinct RP expression patterns across brain regions and between neurons, astrocytes and microglia, including neuron-enriched RPs Rpl13a and Rps10. Analysis of RP paralogues revealed complex expression relationships with their canonical counterparts, suggesting regulated mechanisms for generating heterogeneous ribosomes. Across brain regions and cell types, Rplp0 and Rpl13a, commonly used normalization references, showed heterogeneous expression, raising important methodological considerations for gene expression studies. Rps24 isoforms exhibited striking cell type-specific expression patterns. Rps24c was predominantly expressed in microglia and was increased by neuroinflammation caused by ageing, neurodegeneration or inflammatory chemicals. Using S24-PKE-specific antibodies, we verified increased expression of this protein variant in brains with AD, PD and HD, and in relevant mouse models. These findings establish heterogeneous RP expression as a feature of brain cell types which may enable cell type-specific translation regulation via specialized ribosomes. This work also identifies Rps24c/S24-PKE as a potential novel marker for neuroinflammation and neurodegeneration and provides new tools for monitoring these responses.


  • Open Access

    Impact of Plasma p‐tau181 on Cognition, Motor Phenotypes, and Disease Course in ALS

    by Elisabeth Kasper, Annaliis Lehto, Nina Nordmann, Oliver Peters, Julian Hellmann, Josef Priller, Eike Jakob Spruth, Gabor C. Petzold, Ina Vogt, Patrick Weydt, et al.

    Phosphorylated tau181 (p‐tau181), an Alzheimer's disease biomarker, was recently evaluated in amyotrophic lateral sclerosis (ALS). We investigated plasma p‐tau181 in 202 ALS/ALS‐FTD patients and 94 healthy controls, assessing cognitive performance, motor function, and longitudinal dynamics. Plasma p‐tau181 and NfL were significantly elevated in ALS, with p‐tau181 increasing over 1 year while NfL remained stable. Neither marker correlated with cognitive performance, and only NfL was associated with disease severity and progression. Plasma p‐tau181 was higher in patients with predominant lower motor neuron involvement. The results indicate that p‐tau181 reflects peripheral processes in ALS, providing a complementary, mechanistically distinct biomarker from NfL.


  • Open Access

    Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia

    by Lena Marth, Francisco J. Martinez-Murcia, Juan-Manuel Górriz-Sáez, Jannis Denecke, Michael Ewers, Catharina Prix, Anna Christina Stockbauer, Alexander Maximilian Bernhardt, Olivia Wagemann, Elisabeth Wlasich, et al.

    Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217], p < 0.003), sex (1.376 [0.666-2.087], p < 0.001), and the interaction between the nonfluent variant of PPA and sex (-1.940 [-3.242 to -0.638], p = 0.004) showed a significant effect on the active behavioral phenotype, with symptom severity increasing over time and being most pronounced in men with bvFTD. Patients with bvFTD exhibited more severe passive behavioral symptoms compared with any other diagnostic group. For the affective phenotype, a significant interaction between time and sex (0.063 [0.010-0.117], p = 0.021) indicated a progressive increase in symptom severity in men over time. Furthermore, we found robust neuroanatomical correlations of passive behavioral symptoms with subcortical and bilateral frontal and cingulate cortical atrophy. Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.